Current status of high dose chemotherapy in breast cancer.

S. Glück, D. Stewart

Research output: Contribution to journalArticle

Abstract

To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.

Original languageEnglish
Pages (from-to)30-32
Number of pages3
JournalPrzeglad Lekarski
Volume57 Suppl 1
StatePublished - Aug 17 2000
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Sample Size
Therapeutics
Quality of Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glück, S., & Stewart, D. (2000). Current status of high dose chemotherapy in breast cancer. Przeglad Lekarski, 57 Suppl 1, 30-32.

Current status of high dose chemotherapy in breast cancer. / Glück, S.; Stewart, D.

In: Przeglad Lekarski, Vol. 57 Suppl 1, 17.08.2000, p. 30-32.

Research output: Contribution to journalArticle

Glück, S & Stewart, D 2000, 'Current status of high dose chemotherapy in breast cancer.', Przeglad Lekarski, vol. 57 Suppl 1, pp. 30-32.
Glück S, Stewart D. Current status of high dose chemotherapy in breast cancer. Przeglad Lekarski. 2000 Aug 17;57 Suppl 1:30-32.
Glück, S. ; Stewart, D. / Current status of high dose chemotherapy in breast cancer. In: Przeglad Lekarski. 2000 ; Vol. 57 Suppl 1. pp. 30-32.
@article{83249ccab44f444fab7c5f59c50345d1,
title = "Current status of high dose chemotherapy in breast cancer.",
abstract = "To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.",
author = "S. Gl{\"u}ck and D. Stewart",
year = "2000",
month = "8",
day = "17",
language = "English",
volume = "57 Suppl 1",
pages = "30--32",
journal = "Przeglad Lekarski",
issn = "0033-2240",
publisher = "Fundacja Lekarzy Polskich-Pro-Medica",

}

TY - JOUR

T1 - Current status of high dose chemotherapy in breast cancer.

AU - Glück, S.

AU - Stewart, D.

PY - 2000/8/17

Y1 - 2000/8/17

N2 - To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.

AB - To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033658885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033658885&partnerID=8YFLogxK

M3 - Article

C2 - 10822993

AN - SCOPUS:0033658885

VL - 57 Suppl 1

SP - 30

EP - 32

JO - Przeglad Lekarski

JF - Przeglad Lekarski

SN - 0033-2240

ER -